Multidisciplinary

High-flow nasal cannula oxygen therapy better than CPAP in preterm infants

Tristan Manalac, 16 minutes ago

Compared with continuous positive airway pressure (CPAP), respiratory support using high-flow nasal cannula oxygen therapy (HNFC) appears to yield better clinical outcomes in preterm infants, according to a recent meta-analysis.

Vilobelimab augments treatment armamentarium for critically ill COVID-19 patients

Audrey Abella, 16 minutes ago

In the phase III part of the PANAMO trial, the anti-C5a monoclonal antibody vilobelimab, when added to standard of care (SoC), improved survival in COVID-19 patients who required invasive mechanical ventilation (IMV).

CGM improves HbA1c levels in T1D

Roshini Claire Anthony, 19 hours ago

Continuous glucose monitoring (CGM) with alarms for high or low blood sugar levels better controlled HbA_1c levels than personal fingerstick monitoring in patients with type 1 diabetes (T1D), results of the FLASH-UK trial showed.

When dengue fever becomes severe

01 Nov 2022

Dengue has been around for more than a century from the first reported outbreak in 1902,1 with experts advising healthcare professionals (HCPs) from time to time to alert HCPs to the threats of dengue. This is because the dengue virus has been evolving and can cause severe illness especially among vulnerable patients regardless of age. In this fourth interview of a series focused on dengue, Dr Shanthi Ratnam, Consultant Physician and Intensivist, elaborated on the risks, impact and management of dengue, and advocated dengue as a public health priority.

Pregabalin mainstay of treatment in painful diabetic neuropathy

01 Nov 2022

At the recent Novugen Expert Forum, held in Penang, Dr Khaw Chong Hui discussed the prevalence of painful diabetic neuropathy (PDN), role of pregabalin in the treatment of PDN, its place in treatment recommendations of major international pain guidelines and its proven safety and efficacy.

Molecular Pathogenesis and Current Treatment Landscape In MPN, With A Focus On PV

01 Nov 2022

The recent Northern Haematology Update, held in Penang, saw Dr Christopher Ng, Dr Tan Sui Keat and Dr Carol Goh present on various aspects of myeloproliferative neoplasms (MPN)and its management. Dr Christopher Ng, a haematology trainee at Hospital Sultanah Bahiyah, Kedah, discussed the role of mutations as drivers of disease, with a focus on polycythaemiavera (PV) and essential thrombocythaemia (ET).

Iliadin® nasal drops safe, effective for infants and young children

01 Nov 2022

liadin® (oxymetazoline hydrochloride 0.01%) has been specially formulated in low dose to treat acute rhinitis, vasomotor rhinitis, allergic rhinitis, paranasal sinusitis, and nasal congestion in infants and young children. Iliadin®, the original brand for oxymetazoline has been in the market for over 60 years. Iliadin® is a direct-acting sympathomimetic with marked alpha-adrenergic activity that causes vasoconstriction—reduces swelling and congestion—when applied to mucous membranes.

Timely treatment of patients at risk for severe COVID-19 prevents severe outcomes

Dr. Asok Kurup, Dr. Alex Soriano, 31 Oct 2022

Despite widespread uptake of vaccinations, COVID-19 remains a serious health issue for high-risk patients, owing to the emergence of new variants of concern (VOCs), waning immunity, and breakthrough infections.

At a recent symposium in Singapore, esteemed experts Dr Asok Kurup, Consultant Infectious Diseases Physician at Mount Elizabeth Medical Centre, Singapore, and Dr Alex Soriano, Head of Infectious Diseases Department, Hospital Clínic of Barcelona and Assistant Professor, University of Barcelona, Spain, gave insights on the evolution of global trends since the start of the COVID-19 pandemic and discussed key challenges in managing high-risk patients with COVID-19 in the ICU. They also highlighted early treatment strategies to minimize the burden of COVID-19 on healthcare systems.

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

Elvira Manzano, 04 Oct 2022

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

CT angiography may increase potential recipients of EVT for acute ischaemic stroke

CT angiography may increase potential EVT recipients for acute ischaemic stroke

Roshini Claire Anthony, 27 Nov 2022

Using collateral flow findings, as seen on computed tomographic (CT) angiography, may widen the population who can undergo late endovascular treatment (EVT) for acute ischaemic stroke (AIS), according to findings of the MR CLEAN-LATE trial.

Lower all-cause death, fewer HF events with empagliflozin in acute HF

Roshini Claire Anthony, 25 Nov 2022

Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.

Letermovir as good as valganciclovir for CMV prophylaxis

Elaine Soliven, 25 Nov 2022

The novel antiviral letermovir is as good as the current standard of care valganciclovir in preventing cytomegalovirus (CMV) infection in post-kidney transplant patients, but with less toxicity, according to a phase III trial presented at IDWeek 2022.

Post-surgery emergence delirium in kids has no long-term impact

Roshini Claire Anthony, 23 Nov 2022

The use of general anaesthesia (GA) in children undergoing elective surgeries does not lead to long-term deterioration in behavioural outcomes, according to a study presented at Anesthesiology 2022.

TB rates elevated after ART initiation in PLHIV

Roshini Claire Anthony, 21 Nov 2022

People living with HIV (PLHIV) who initiate antiretroviral therapy (ART) are at an increased risk of developing tuberculosis (TB), particularly in the first 3 months after starting ART, according to a study presented at HIV Glasgow 2022.

Low use of CVD prevention strategies in people with HIV

Roshini Claire Anthony, 18 Nov 2022

There is an underutilization of cardiovascular disease (CVD) prevention strategies in people living with HIV (PLHIV) who are at risk of CVD, according to a study presented at HIV Glasgow 2022.